Literature DB >> 22893335

Niacin added to statins for cardiovascular disease.

Michael R Kolber1, Noah Ivers, G Michael Allan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22893335      PMCID： PMC3418982     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  12 in total

1.  Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health.

Authors:  Rodney A Hayward; Harlan M Krumholz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-01

Review 2.  Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.

Authors:  Rodney A Hayward; Timothy P Hofer; Sandeep Vijan
Journal:  Ann Intern Med       Date:  2006-10-03       Impact factor: 25.391

Review 3.  2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

Authors:  Jacques Genest; Ruth McPherson; Jiri Frohlich; Todd Anderson; Norm Campbell; André Carpentier; Patrick Couture; Robert Dufour; George Fodor; Gordon A Francis; Steven Grover; Milan Gupta; Robert A Hegele; David C Lau; Lawrence Leiter; Gary F Lewis; Eva Lonn; G B John Mancini; Dominic Ng; Glen J Pearson; Allan Sniderman; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2009-10       Impact factor: 5.223

4.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

Review 5.  Interventions to improve adherence to lipid lowering medication.

Authors:  Angela Schedlbauer; Philippa Davies; Tom Fahey
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

6.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

7.  Coronary drug project: experience with niacin. Coronary Drug Project Research Group.

Authors:  K G Berge; P L Canner
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

9.  Extended-release niacin or ezetimibe and carotid intima-media thickness.

Authors:  Allen J Taylor; Todd C Villines; Eric J Stanek; Patrick J Devine; Len Griffen; Michael Miller; Neil J Weissman; Mark Turco
Journal:  N Engl J Med       Date:  2009-11-15       Impact factor: 91.245

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.